ACEA Biosciences, Inc.
6779 Mesa Ridge Road
About ACEA Biosciences, Inc.
Founded in 2002, ACEA Biosciences, Inc. is a privately owned biotechnology company that is pioneering the development and commercialization of high performance, cutting edge cell analysis instruments for life science research and clinical diagnostics.
Employing noninvasive impedance microelectrodes in automated high-throughput plate formats, our xCELLigence® Real-Time Cell Analysis (RTCA) instruments maximize the physiological relevance of data extracted from in vitro cellular assays. These instruments enable label-free, real-time monitoring of cell proliferation, cell size/morphology, cell-substrate attachment quality, and cell invasion/migration. By eliminating the time- and labor-intensive steps of traditional methods, RTCA vastly improves efficiency and overall productivity. Moreover, the flexibility, sensitivity, and reproducibility of RTCA make it a standout amongst cell-based assay platforms.
ACEA is also helping to revolutionize the field of flow cytometry by designing and producing high performance, customizable benchtop cytometers at accessible price points. By including features such as 13 fluorescence detection channels with 3 lasers, direct volumetric based cell counting, and a versatile high throughput walkaway autosampler, ACEA’s line of NovoCyte® flow cytometers is raising the bar for what is expected of benchtop machines.
xCELLigence® and NovoCyte® instruments are currently being used worldwide in academic, industrial, and hospital labs for preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, clinical diagnostics, and basic research.
26 articles with ACEA Biosciences, Inc.
ACEA Biosciences – A Part of Agilent Launches the xCELLigence RTCA ePacer to improve the Quality and Functionality of hiPSC-Cardiomyocytes for Drug Discovery, Safety Pharmacology, and Cardiac Disease Research
On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacerTM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore.
Acquisition Brings Together Two Pioneers in Cellular Function and Metabolism Measurements
Acquisition adds a differentiated portfolio and organizational capabilities in the fast-growing cell analysis market
Cell Analysis Just Got Better!
ACEA Biosciences is a privately owned biotechnology company which develops cutting edge instrumentation for cell analysis. The company has just introduced the xCELLigence RTCA S16, which is the ideal entry level model for exploratory studies in cell biology.
By using the xCELLigence instrument to monitor the attachment and growth of Acinetobacter baumannii in real-time, University of South Florida graduate student Jessie Adams has discovered key genes/proteins that enable this pathogen to persist in the surface-attached biofilm state.
With the goal of improving the antimicrobial drug discovery process, scientists in Finland will employ xCELLigence technology to identify compounds active against E. coli biofilms.
ACEA Biosciences Partners with the Cancer Research Institute in Support of Cancer Immunotherapy Month
As a leading innovator in the development of tools for the cancer research laboratory, ACEA Biosciences, The Cell Analysis Company, is partnering with the nonprofit Cancer Research Institute (CRI) to proudly support their annual global awareness campaign, Cancer Immunotherapy Month, taking place in June.
New High Performance 4-Laser Benchtop Flow Cytometer to be Launched by ACEA Biosciences at CYTO 2018
Continuing its track record as an innovator in in flow cytometry, today, ACEA Biosciences released the most advanced benchtop flow cytometer on the market. The NovoCyte Quanteon flow cytometer builds upon its wildly successful predecessor, the NovoCyte, to provide an expanded set of capabilities that easily accommodates the large, multi-color panels found in today’s highly progressive flow cytometry laboratories.
Today ACEA Biosciences, a pioneer of instrumentation for cell-based assays, announced the launch of AccuWound 96, a tool which simultaneously generates identical scratch wounds in every well of a 96-well plate.
ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.
Physiologically Relevant Testing of Cancer Immunotherapies Now Possible with Real-Time Potency Assay
In a research article just published in PLOS ONE, scientists at ACEA Biosciences, a biotechnology company focused on the development of high performance cell analysis instruments, investigate the efficacy of a real-time in vitro potency assay for evaluating various immunotherapy treatments against both solid and liquid tumor cells. Immunotherapy, a powerful approach in which a patient’s immune system is prompted to attack cancerous cells, continues to show tremendous therapeutic potential.
At last week’s 57th Annual Meeting and ToxExpo (in San Antonio, Texas), the Society of Toxicology announced “Deconvoluting Kinase Inhibitor Induced Cardiotoxicity” as its paper of the year for 2017.
ACEA Release: Live Cell Analysis Using xCELLigence Instruments: Searchable Library of Over 1,400 Publications Now Online
ACEA launched a comprehensive and searchable online library. “By compiling all these publications in a single location, our hope is to make this information, including protocols.
ACEA Release: Real-Time Monitoring of Cancer Cells Under Hypoxic Conditions Reveals Novel Regulator of Proliferation and Migration
A team of Korean scientists headed by Bu Young Choi at Seowon University have described an elegant solution to this challenge by placing an xCELLigence Real-Time Cell Analyzer (RTCA) directly within a hypoxia chamber.
ACEA Release: Real-Time Monitoring of Melanoma Cell Invasion Helps Scientists Elucidate Key Regulators of Metastasis
A team of Italian scientists reported this week that blocking the interaction between urokinase receptor (uPAR) and formyl peptide receptor type 1 (FPR1) suppresses the ability of melanoma cells to migrate, invade through an extracellular matrix, and to burrow through a layer of endothelial cells.
Asthma Intervention: Novel Impedance-Based Assay Monitors the Contraction and Relaxation of Smooth Muscle Cells and Fibroblasts in Real-Time
Contraction and relaxation of smooth muscle cells and fibroblasts within the bronchial airways dramatically affects airflow, and being able to modulate these processes is critical for treating asthma and allergic responses.
ACEA Biosciences and Ncardia Announce Global Partnership to Provide Solutions for Cardiac Drug Discovery and Cardiac Safety Assessment
This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities.
ACEA Biosciences Release: Characterizing Bacteriophage-Derived Enzymes That Degrade Staphylococcus Biofilms
Biofilms are surface-attached communities of bacterial or fungal cells that are enmeshed in an extensive extracellular matrix which makes them more resistant to both antibiotics and the immune system.
ACEA Biosciences, Inc. Announces Successful Completion Of Phase I Clinical Study Of Novel Autoimmune Disease Drug